(Reuters) -Abbott Laboratories ( ABT ) raised its annual profit forecast and beat Wall Street estimates for second-quarter earnings on Thursday, buoyed by strong sales of its cardiac and diabetes care devices.

The company's medical devices segment, like the rest of the industry, has benefited from a recovery in sales of heart valves and pacemakers in recent quarters as more people, especially older adults, opted for surgeries deferred during the pandemic.

The business was also bolstered by strong sales of diabetes care devices, especially of FreeStyle Libre. Sales of the glucose monitors climbed 18% to $1.6 billion.

Overall, medical devices sales rose 10.2% to $4.73 billion, ahead of the average analyst estimate of $4.66 billion.

The company now expects a profit of $4.61 to $4.71 per share for the full year, compared with its prior forecast of $4.55 to $4.70.

On an adjusted basis, quarterly profit of $1.14 per share beat analysts' average estimate of $1.10, according to LSEG data.

(Reporting by Pratik Jain, Puyaan Singh and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)